Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Zacks News
Why Is Quest Diagnostics (DGX) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Jumps: Stock Rises 9.3%
by Zacks Equity Research
Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sweta Jaiswal
The wave of digital transition is helping players in the Zacks Medical Info Systems industry to open up bountiful opportunities for investors.
Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
Quest Diagnostics (DGX) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Pick Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics Ties Up With RMC to Deliver Lab Services
by Zacks Equity Research
Quest Diagnostic's (DGX) partnership with RMC is set to better the quality of patient care.
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Quest Diagnostics (DGX) Q4 Earnings Meet Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Earnings Preview: Quest Diagnostics (DGX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' Core Diagnostics Strong Amid Several Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
Quest Diagnostics (DGX) Divests India Business to Strand
by Zacks Equity Research
Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.
Amazon Eyeing Diagnostic Space to Gather Steam in Healthcare
by Zacks Equity Research
Amazon's (AMZN) growing healthcare initiatives are likely to aid its growth in the healthcare supply chain management market.
Myriad Genetics Announces Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.
Quest Diagnostics Rides on Product Launches, Strategic Deals
by Zacks Equity Research
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
Near-Term Outlook for Medical Information Systems Industry
by Zacks Equity Research
The wave of digital transition is helping companies in the Zacks Medical Info Systems industry to create opportunities for investors.
Company News For Nov 30, 2018
by Zacks Equity Research
Companies In The News Are: DLTR,ANF,DGX,NLSN
Quest Diagnostics to Buy Laboratory Services Unit in Midwest
by Zacks Equity Research
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.